Multi-step virtual screening to develop selective DYRK1A inhibitors

被引:11
|
作者
Koyama, Tomoko [1 ]
Yamaotsu, Noriyuki [1 ]
Nakagome, Izumi [1 ]
Ozawa, Shin-ichiro [1 ]
Yoshida, Tomoki [1 ]
Hayakawa, Daichi [1 ]
Hirono, Shuichi [1 ]
机构
[1] Kitasato Univ, Sch Pharm, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan
来源
JOURNAL OF MOLECULAR GRAPHICS & MODELLING | 2017年 / 72卷
关键词
DYRK1A; Kinase selectivity; In silico screening; Free energy decomposition; Discriminant analysis; FORCE-FIELD; BINDING; KINASES; ANALOGS; DESIGN; REGULARIZATION; SIMULATIONS; ACTIVATION; SCAFFOLDS; COUMARINS;
D O I
10.1016/j.jmgm.2017.01.014
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Developing selective inhibitors for a particular kinase remains a major challenge in kinase-targeted drug discovery. Here we performed a multi-step virtual screening for dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors by focusing on the selectivity for DYRK1A over cyclin-dependent kinase 5 (CDK5). To examine the key factors contributing to the selectivity, we constructed logistic regression models to discriminate between actives and inactives for DYRK1A and CDK5, respectively, using residue-based binding free energies. The residue-based parameters were calculated by molecular mechanics-generalized Born surface area (MM-GBSA) decomposition methods for kinase-ligand complexes modeled by computer ligand docking. Based on the findings from the logistic regression models, we built a three-dimensional (3D) pharmacophore model and chose filter criteria for the multi-step virtual screening. The virtual hit compounds obtained from the screening were assessed for their inhibitory activities against DYRK1A and CDK5 by in vitro assay. Our screening identified two novel selective DYRK1A inhibitors with IC50 values of several mu M for DYRK1A and >100 mu M for CDK5, which can be further optimized to develop more potent selective DYRK1A inhibitors. (C) 2017 Elsevier Inc.
引用
收藏
页码:229 / 239
页数:11
相关论文
共 50 条
  • [41] A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors
    Shekfeh, Suhaib
    Caliskan, Burcu
    Fischer, Katrin
    Yalcin, Tansu
    Garscha, Ulrike
    Werz, Oliver
    Banoglu, Erden
    CHEMMEDCHEM, 2019, 14 (02) : 273 - 281
  • [42] Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia
    Carey-Smith, Shannon L.
    Simad, Maryam H.
    Panchal, Kunjal
    Aya-Bonilla, Carlos
    Smolders, Hannah
    Lin, Sang
    Armitage, Jesse D.
    Nguyen, Vivien T.
    Bentley, Kathryn
    Ford, Jette
    Singh, Sajla
    Oommen, Joyce
    Laurent, Anouchka P.
    Mercher, Thomas
    Crispino, John D.
    Montgomery, Andrew P.
    Kassiou, Michael
    Besson, Thierry
    Deau, Emmanuel
    Meijer, Laurent
    Cheung, Laurence C.
    Kotecha, Rishi S.
    Malinge, Sebastien
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2309 - 2315
  • [43] Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
    Yasushi Ogawa
    Yosuke Nonaka
    Toshiyasu Goto
    Eriko Ohnishi
    Toshiyuki Hiramatsu
    Isao Kii
    Miyo Yoshida
    Teikichi Ikura
    Hiroshi Onogi
    Hiroshi Shibuya
    Takamitsu Hosoya
    Nobutoshi Ito
    Masatoshi Hagiwara
    Nature Communications, 1
  • [44] Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A
    Miyazaki, Yuka
    Kikuchi, Masaki
    Umezawa, Koji
    Descamps, Aurelie
    Nakamura, Daichi
    Furuie, Gaku
    Sumida, Tomoe
    Saito, Kanako
    Kimura, Ninako
    Niwa, Takashi
    Sumida, Yuto
    Umehara, Takashi
    Hosoya, Takamitsu
    Kii, Isao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227
  • [45] Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics
    Pustelny, Katarzyna
    Grygier, Przemyslaw
    Barzowska, Agata
    Pucelik, Barbara
    Matsuda, Alex
    Mrowiec, Krzysztof
    Slugocka, Emilia
    Popowicz, Grzegorz M.
    Dubin, Grzegorz
    Czarna, Anna
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [46] Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics
    Katarzyna Pustelny
    Przemyslaw Grygier
    Agata Barzowska
    Barbara Pucelik
    Alex Matsuda
    Krzysztof Mrowiec
    Emilia Slugocka
    Grzegorz M. Popowicz
    Grzegorz Dubin
    Anna Czarna
    Scientific Reports, 13
  • [47] Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
    Ogawa, Yasushi
    Nonaka, Yosuke
    Goto, Toshiyasu
    Ohnishi, Eriko
    Hiramatsu, Toshiyuki
    Kii, Isao
    Yoshida, Miyo
    Ikura, Teikichi
    Onogi, Hiroshi
    Shibuya, Hiroshi
    Hosoya, Takamitsu
    Ito, Nobutoshi
    Hagiwara, Masatoshi
    NATURE COMMUNICATIONS, 2010, 1
  • [48] Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule
    Wu, Yi-Wen
    Huangfu, Wei-Chun
    Lin, Tony Eight
    Peng, Chao-Hsiang
    Tu, Huang-Ju
    Sung, Ting-Yi
    Sung, Tzu-Ying
    Yen, Shih-Chung
    Pan, Shiow-Lin
    Hsu, Kai-Cheng
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 259
  • [49] Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
    Anderson, Kevin
    Chen, Yi
    Chen, Zhi
    Dominique, Romyr
    Glenn, Kelli
    He, Yang
    Janson, Cheryl
    Luk, Kin-Chun
    Lukacs, Christine
    Polonskaia, Ann
    Qiao, Qi
    Railkar, Aruna
    Rossman, Pamela
    Sun, Hongmao
    Xiang, Qing
    Vilenchik, Masha
    Wovkulich, Peter
    Zhang, Xiaolei
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) : 6610 - 6615
  • [50] Naturally occurring caffeic acid phenethyl ester from chestnut honey-based propolis and virtual screening towards DYRK1A
    Arslan, Idris
    NATURAL PRODUCT RESEARCH, 2024,